The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis

Sarah Burkill1,2*, Pia Vattulainen3, Yvonne Geissbuehler4, Meritxell Sabido Espin5, Catrinel Popescu6, Kiliana Suzart-Woischnik7, Jan Hillert8, Miia Artama9, Auli Verkkoniemi-Aholah10, Kjell-Morten Myhr11, Sven Cnattingius2, Pasi Korhonen3, Scott Montgomery2,12,13, Shahram Bahmanyar1,2

1 Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden, 2 Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 3 EPID research, Helsinki, Finland, 4 Novartis Pharma AG, Basel, Switzerland, 5 Merck group, Darmstadt, Germany, 6 Biogen, Maidenhead, United Kingdom, 7 Bayer AG, Berlin, Germany, 8 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, 9 National Institute for Health and Welfare, Helsinki, Finland, 10 Department of Neurology, Helsinki University, Helsinki, Finland, 11 Department of Clinical Medicine, University of Bergen, Bergen, Norway, 12 Clinical Epidemiology and Biostatistics School of Medical Sciences, Örebro University, Örebro, Sweden, 13 Department of Epidemiology and Public Health, University College London, London, United Kingdom

* sarah.burkill@ki.se

Abstract

Background
Interferon-beta (IFN-beta) is a commonly used treatment for multiple sclerosis (MS). Current guidelines recommend cessation of treatment during pregnancy, however the results of past studies on the safety of prenatal exposure to IFN-beta have been conflicting. A large scale study of a population of MS women is therefore warranted.

Objectives
To assess whether, among those born to women with MS, infants prenatally exposed to IFN-beta show evidence of smaller size at birth relative to infants which were not prenatally exposed to any MS disease modifying drugs.

Methods
Swedish and Finnish register data was used. Births to women with MS in Sweden and Finland between 2005–2014 for which a birth measurement for weight, height, and head circumference was available were included. The exposure window was from 6 months prior to LMP to the end of pregnancy.
Introduction

Multiple sclerosis (MS) is an immune mediated disease causing demyelination and axonal loss in the central nervous system (CNS) [1]. Women with MS often cease treatment during pregnancy, in part due to immunological adaptations during pregnancy including suppression of T-cell activity [2], which occur to allow foetal growth without the foetus being recognised as a foreign agent by the immune system, often reducing symptoms [3]. Interferon beta (IFN-beta) is a commonly used disease modifying treatment for MS, with current guidelines recommending cessation during pregnancy. Pregnant women are often excluded from clinical trials, meaning the effects of prenatal exposure are not known, resulting in a preference to cease treatment. If the pregnancy is planned, decisions need to be made as to whether treatment should be continued. However not all pregnancies are planned and some women will conceive whilst on treatment, making foetal exposure to IFN-beta inevitable in some instances. The possible effects of this are not known with certainty. Results from smaller scale studies generally show no adverse pregnancy outcomes for mothers exposed to IFN-beta during pregnancy [4–8]. However, some studies have concluded that exposure could potentially be detrimental, making the benefit–risk assessment for mother and child and therefore the decision to continue or discontinue treatment after conception difficult [9]. Given conflicting outcomes in past research [4–9], an investigation into potential adverse pregnancy outcomes related to foetal exposure to IFN-beta using larger populations of women with MS rather than smaller samples is therefore warranted.

This study utilized administrative data from Sweden and Finland to compare birth measurements (birth weight, height, and head circumference) of infants of women with MS exposed to IFN-beta, and infants of women with MS unexposed to IFN-beta during pregnancy. A comparison of infants of women with MS exposed to IFN-beta and unexposed allowed for examination of the impact of IFN-beta treatment on pregnancy outcomes.

Methods

Study population and data sources

Pregnancies resulting in a live birth to women with a diagnosis of MS were identified using the Medical Birth Registers between the years of 2005 and 2014 in Sweden and Finland. These dates were selected because the PDR in Sweden began in 2005, so it would not be possible to...
Pre-natal interferon-beta exposure and birth measurements

Exposure and outcome

Exposure to IFN-beta was counted as having occurred if the individual collected a prescription of IFN-beta during the exposure window, here defined as up to 6 months prior to the last menstrual period (LMP) until the end of the pregnancy according to the PDR of Sweden or Finland, or if a date of initiation for IFN-beta was recorded in the MSR in Sweden. It was assumed that the woman would have been exposed to IFN-beta in the 3 months before LMP or later, because the prescriptions are intended to last 3 months. Exposure to any MS DMD was also identified using the same registers and exposure window (see S1 Table for the list of ATC codes) aside from cladribine and mitoxantrone, for which exposure 6 months prior (purchase 9 months prior) to LMP was considered as exposed.

Within the MSR, exposure definitions are reliant on dates of treatment initiation and cessation. The accuracy of using such dates to determine exposure may be considered questionable. Clinicians who only temporarily cease treatment due to the pregnancy would not necessarily consider this a cessation of treatment. In these instances, date of cessation indicating the treatment was stopped during pregnancy would go unrecorded. It is also possible that no cessation date was recorded because the woman continued treatment during the exposure window. To examine whether results changed when applying different exposure criteria from the MSR, a sensitivity analysis identified all pregnancies with recorded treatment before the 6 months prior to LMP exposure window but with no cessation date during the exposure window. This analysis provides numbers exposed and mean values for each outcome, rather than comprising the main definition due to the previously mentioned limitations. It was only possible to conduct this sensitivity analysis using Swedish data, since such information is not available in the Finnish registers.

Pregnancies exposed to IFN-beta only were compared to pregnancies unexposed to any MS DMD. Birth measurements for weight in grams, height in cm, and head circumference in cm were used in a continuous form, and information was taken directly from the Medical Birth Registers of Sweden and Finland.
Statistical analysis

Linear regression using generalized estimating equations (GEEs) was undertaken in which the mother’s ID was used as a cluster identifier which demarcates siblings. Maternal age at LMP, gestational age in weeks, maternal smoking status, and within Sweden highest maternal educational attainment (separated into compulsory school or less, upper secondary, or higher education) were considered to be possible confounders, and included in the adjusted models. Sex of the newborn was also included in the model due to its association with birth measurements. An analysis studying differently exposed siblings was also undertaken and included the same confounders as covariates. Adjusting for maternal age at LMP meant birth order was considered in this model.

A sensitivity analysis which compared women exposed to any MS DMD (including but not limited to IFN-beta) to women unexposed to any MS DMD was also undertaken to assess whether the outcomes differed to when IFN-beta exposure only was studied.

Continuous measures which compare mean measurements between groups are the primary outcomes used in this paper.

Ethics statement

In Finland, the study was given a positive opinion by the Helsinki University Hospital Ethics Committee (Finland; 159/13/03/00/2016). Data permit approvals were granted by the National Institute for Health and Welfare (Dnro THL/635/5.05.00/2016) and the Social Insurance Institution (Dnro 42/522/2016). In Sweden, the study was approved by the Regional Ethical Review Board in Stockholm (Sweden; 2016/874-31/2). Data permit approvals were granted by National Board of Health and Welfare (Dnr 23981/2016) and Swedish MS Registry (Dnr 53). All individuals within Sweden and Finland are automatically included in administrative records through entry into national registers at birth or immigration. Informed consent is not gained for this. These databases are primarily administrative in nature, and are not set up with research as the intended outcome, however they are commonly used for such purposes. The datasets are held at the institutions listed in the data access statement, and were fully anonymised by the holding institutions before delivery.

Results

In Sweden, 411 pregnancies were identified as exposed to IFN-beta during the exposure window for which all birth measurements were available, and 835 pregnancies were counted as unexposed to any MS DMD. The corresponding numbers for Finland were 232 and 331, respectively. Within Sweden, there were 1131, and within Finland 442 women with MS registered as having a pregnancy during the study time frame. In Sweden, there were 101 pregnancies comprised of 50 sibling sets identified as being differently exposed to IFN-beta. The corresponding numbers for Finland were 83 pregnancies comprised of 41 sibling sets. The study population characteristics showed most women in Sweden had received higher education (studying at university) as their highest educational attainment (data on education were unavailable in Finland), and had a parity of 2 overall. When considering all pregnancies, the unexposed cohort had on average a slightly older age at LMP relative to the exposed cohort in Sweden, and in Finland the ages were very similar at LMP (Table 1). Gestational age at birth was not significantly different among the exposed and unexposed cohorts, with mean gestational age of 39.7 weeks for the exposed and 39.5 weeks (p = 0.10) for the unexposed cohorts in Sweden, and 39.4 weeks for the exposed and 39.5 weeks (p = 0.67) for the unexposed cohorts in Finland. Births prior to 22 weeks are not recorded in the medical birth registers. Very early
births under 32 weeks are rare. S1–S3 Figs show the distribution of birth measurements and allow for identification of outliers.

In the adjusted analyses, infants prenatally exposed to IFN-beta were on average 28 grams heavier (p = 0.17) in Sweden, and 50 grams lighter (p = 0.26) in Finland than those unexposed (Table 2). For birth height, those exposed to IFN-beta were 0.01 cm longer (p = 0.95) in Sweden, and 0.02 cm shorter (p = 0.92) in Finland compared to those unexposed. For head circumference, those in Sweden had measurements 0.14 cm larger (p = 0.13) and in Finland 0.22 cm smaller (p = 0.15) relative to those unexposed (unadjusted analyses shown in Table 2, adjusted analyses shown in Table 3).
Analysis of groups of siblings in which at least one sibling was exposed, and at least one sibling was unexposed was undertaken (see Tables 2 and 3). Overall, differences between siblings exposed and siblings unexposed to IFN-beta during pregnancy were minimal, and not statistically significant. The same was true when considering exposure to any MS DMD, relative to non-exposure to MS DMD (see S3–S5 Tables).

Discussion

Infants born to women with MS exposed to IFN-beta during pregnancy did not show evidence of decreased intrauterine growth relative to infants born to MS women unexposed to IFN-beta during pregnancy. There were also no differences in mean gestational age at birth. No differences were found when comparing infants prenatally exposed to any MS DMD, relative to infants not exposed to MS DMD. This confirms evidence from some past studies which report no adverse effects for infants prenatally exposed to IFN-beta[5, 7, 10], and refutes the findings of other studies which have found IFN-beta is associated with birth measurement[11].

Birth measurements which are substantially below average have been reported to be associated with a number of adverse health outcomes, including behavioural difficulties such as ADHD[12], and other health conditions including coronary heart disease and diabetes[13, 14], although the extent to which these effects are confounded by social or genetic factors is incompletely understood[15]. The increased risks of adverse outcomes later in life highlights the importance of studying such measures.

Gestational age is one of the most critical factors determining birth measurements[16], with expected foetal weight gain of 24–26 grams per day in the third trimester for low risk pregnancies[17]. Gestational ages at birth were comparable across exposure groups, and maternal ages at LMP, indicating exposure to IFN-beta does not result in earlier gestational

| Unadjusted | Adjusted* |
|------------|-----------|
| Weight     | P-value   | Height | P-value | Head circumference | P-value |
| Sweden     |           |        |         |            |         |
| Overall    | 51.1 (37.4) | 0.17   | 0.12 (0.2) | 0.48 | 0.20 (0.1) | 0.08 |
| Differently exposed siblings | 128.8 (110.0) | 0.24   | 0.53 (0.5) | 0.27 | 0.31 (0.3) | 0.34 |
| Finland    |           |        |         |            |         |
| Overall    | -52.8 (59.6) | 0.38   | -0.10 (0.3) | 0.74 | -0.26 (0.2) | 0.21 |
| Differently exposed siblings | -198.2 (126.7) | 0.12   | -0.71 (0.8) | 0.36 | -0.57 (0.5) | 0.3 |

*Adjusted for gestational age, sex of the newborn, smoking status of the mother, and maternal age at LMP

https://doi.org/10.1371/journal.pone.0227120.t002

Table 3. GEE’s adjusted- differences in mean weight, height, and head circumference between exposed and unexposed cohorts.
age at birth, and will therefore not have an impact on birth measurements through this mechanism.

One explanation as to why IFN-beta may not be influencing birth measurements or gestational age could be due to its pharmacokinetic characteristics. The placental barrier is a semi-permeable tissue which separates foetal and maternal blood, and is only permeable for substances with a low molecular weight (between 600 and 800 Dalton)[18]. IFN-beta is categorized as a polypeptide with a molecular weight of 22. kDa (kiloDalton) for IFN-beta 1a and 18.5kDa for IFN-beta 1b[19], which is too large to permeate the placental barrier. The likelihood of IFN-beta therefore being able to directly affect the development of the foetus through permeation of foetal blood is unlikely, and suggests the lack of an effect of IFN-beta on foetal growth measurements is biologically plausible.

The maternal identification numbers included in our data allowed for observation of specific sets of siblings. This was particularly useful, as it enabled us to consider the effect of exposure to IFN-beta on an individual, relative to their unexposed sibling or siblings. In contrast to regular population analysis, sibling analysis controls by design for unmeasured shared familial (genetic and environmental) factors. Differences between the sibling exposure groups for all included birth measurements were not statistically significant for either Sweden or Finland.

Younger women are more likely to be of lower parity, and to have smaller mean birth measurements for their offspring[20]. Previous studies have indicated the effect of young maternal age on low birth height and weight measurements does not persist when behavioural, biological, and socioeconomic confounders have been controlled for[21, 22], indicating that maternal age may primarily be a confounder. Our study indicated the age at LMP for the pregnancies exposed to IFN-beta was on average lower than the age at LMP for the pregnancies unexposed to any MS DMD. This has the potential to influence birth measurements through potentially unmeasured confounders[23], even though maternal age at LMP itself has been included in the adjusted models.

A strength of this register study was our ability to include all women with MS who had a pregnancy that ended with a birth in both Sweden and Finland during the study period. Previous studies have relied on samples which can be self-selecting, and have reduced power due to smaller numbers enrolled than is possible using register data[24]. Inclusion of a population of pregnant women, with information available for all pregnancies to a particular patient group, removes the possibility of selection bias through for example over-recruitment of low- or high-risk pregnancies, improving the reliability of the results.

Potential limitations of the study should also be considered. It was not possible to know whether exposure identified using the Prescribed Drugs Register resulted in an exposed pregnancy, because we cannot be certain the treatment was taken by the mother. Only data which stated the drug had been dispensed was available for prescriptions, with the assumption then made that the treatment was taken as instructed. Previous studies into different treatments have indicated that pregnant women are less likely to adhere to treatment than other patient groups[25, 26], which increases the likelihood that dispensation does not necessarily equate to exposure. Only pregnancies for which information was recorded for all three measurements (weight, height, and head circumference at birth) were included in the study. If missingness is differential by exposure status, bias may be induced. We were limited in the variables we were able to adjust for, due to limited information being provided in registers. For example, potentially informative data on diet and physical activity are not available. A live birth had to have occurred for inclusion in the study population. The Medical Birth Registers of Sweden and Finland record births occurring at 22 weeks or later of pregnancy. Elective terminations are additionally not identifiable in the Swedish data. If the rates of elective termination and spontaneous abortion differ by exposure group, there is the potential for bias to be induced.
In summary, the evidence from this large population based study indicate no association between IFN-beta exposure and fetal growth or gestational age among infants of women with MS.

Supporting information

S1 Fig. Birth weight in grams by gestational age, according to interferon-beta exposure status.
(DOCX)

S2 Fig. Birth height in cms by gestational age, according to interferon-beta exposure status.
(DOCX)

S3 Fig. Head circumference by gestational age, according to interferon-beta exposure status.
(DOCX)

S1 Table. ATC codes and brand names used to identify interferon-beta exposure.
(DOCX)

S2 Table. Exposed to interferon-beta according to all possibly exposed sensitivity analysis (Sweden only).
(DOCX)

S3 Table. Exposure to any MSDMD’s sensitivity analysis.
(DOCX)

S4 Table. GEE OLS unadjusted models.
(DOCX)

S5 Table. GEE OLS adjusted models.
(DOCX)

S6 Table. Exposure to any MSDMD’s all possibly exposed sensitivity analysis (Sweden only).
(DOCX)

Acknowledgments

We would like to acknowledge the European Interferon Beta Pregnancy Study Group for their contribution to this manuscript.

Author Contributions

Conceptualization: Yvonne Geissbuehler, Meritxell Sabido Espin, Catrinel Popescu, Kiliana Suzart-Woischnik, Jan Hillert, Miia Artama, Auli Verkkoniemi-Ahola, Kjell-Morten Myhr, Sven Cnattingius, Pasi Korhonen, Scott Montgomery, Shahram Bahmanyar.

Data curation: Sarah Burkill, Pia Vattulainen.

Formal analysis: Sarah Burkill, Pia Vattulainen.

Methodology: Sarah Burkill, Pia Vattulainen.

Project administration: Sarah Burkill.
Resources: Yvonne Geissbuehler, Meritxell Sabido Espin, Catrinel Popescu, Kiliana Suzart-Woischnik, Jan Hillert, Miia Artama, Auli Verkkoniemi-Ahola, Kjell-Morten Myhr, Sven Cnattungius, Pasi Korhonen, Scott Montgomery, Shahram Bahmanyar.

Supervision: Scott Montgomery, Shahram Bahmanyar.

Writing – original draft: Sarah Burkill.

Writing – review & editing: Sarah Burkill, Pia Vattulainen, Yvonne Geissbuehler, Meritxell Sabido Espin, Catrinel Popescu, Kiliana Suzart-Woischnik, Jan Hillert, Miia Artama, Auli Verkkoniemi-Ahola, Kjell-Morten Myhr, Sven Cnattungius, Pasi Korhonen, Scott Montgomery, Shahram Bahmanyar.

References
1. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 83(3):278–86. https://doi.org/10.1212/WNL.0000000000000560 PMID: 24871874
2. Priddy KD. Immunologic adaptations during pregnancy. J Obstet Gynecol Neonatal Nurs. 1997; 26 (4):388–94. https://doi.org/10.1111/j.1552-6909.1997.tb02720.x PMID: 9252868
3. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. The New England journal of medicine. 2014; 370(23):2211–8. https://doi.org/10.1056/NEJMra1213566 PMID: 24897084
4. Hellwig K, Haghiakia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012; 5(5):247–53. https://doi.org/10.1177/1756285612453192 PMID: 22973421
5. Sandberg-Wolheim M, Alteri E, Moraga MS, Kornmann G. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Multiple sclerosis (Houndmills, Basingstoke, England). 2011; 17(4):423–30.
6. Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther. 2014; 3(2):133–8. https://doi.org/10.1007/s40120-014-0020-y PMID: 26000229
7. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Multiple sclerosis (Houndmills, Basingstoke, England). 2009; 15 (9):1037–42.
8. Vukusic S, Marignier R. Multiple sclerosis and pregnancy in the 'treatment era'. Nature reviews Neurology. 2015; 11(5):280–9. https://doi.org/10.1038/nrneurol.2015.53 PMID: 25896084
9. Reder AT, Oger JF, Kappos L, O'Connor P, Rametta M. Short-term and long-term safety and tolerability of interferon beta-1b in multiple sclerosis. Multiple sclerosis and related disorders. 2014; 3(3):294–302. https://doi.org/10.1016/j.msard.2014.01.005 PMID: 25876467
10. Coyle PK, Sinclair SM, Scheuerle AE, Thorp JM Jr., Albano JD, Rametta MJ. Final results from the Betaseron (interferon beta-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ open. 2014; 4(5):e004536. https://doi.org/10.1136/bmjopen-2013-004536 PMID: 24821713
11. Boskovics R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology. 2005; 65(6):807–11. https://doi.org/10.1212/01.wnl.0000180575.77021.cf PMID: 16186517
12. Mick E, Biederman J, Prince J, Fischer MJ, Faraone SV. Impact of low birth weight on attention-deficit hyperactivity disorder. Journal of developmental and behavioral pediatrics: JDBP. 2002; 23(1):16–22. https://doi.org/10.1097/00004703-200202000-00004 PMID: 11893477
13. Barker DJ. Fetal origins of coronary heart disease. Bmj. 1995; 311(6998):171–4. https://doi.org/10.1136/bmj.311.6998.171 PMID: 7613432
14. Jornayvaz FR, Vollenweider P, Bochud M, Mooser V, Waebker G, Marques-Vidal P. Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study. Cardiovascular diabetology. 2016; 15:73. https://doi.org/10.1186/s12933-016-0389-2 PMID: 27141948
15. Nobile CG, Raffaele G, Altermore C, Pavia M. Influence of maternal and social factors as predictors of low birth weight in Italy. BMC public health. 2007; 7:192. https://doi.org/10.1186/1471-2458-7-192 PMID: 17683559
16. Fok TF, So HK, Wong E, Ng PC, Chang A, Lau J, et al. Updated gestational age specific birth weight, crown-heel length, and head circumference of Chinese newborns. Archives of disease in childhood Fetal and neonatal edition. 2003; 88(3):F229–36. https://doi.org/10.1136/fn.88.3.F229 PMID: 12719398

17. de Jong CL, Francis A, van Geijn HP, Gardosi J. Fetal growth rate and adverse perinatal events. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 1999; 13(2):86–9.

18. Thone J, Thiel S, Gold R, Hellwig K. Treatment of multiple sclerosis during pregnancy—safety considerations. Expert Opin Drug Saf. 2017; 16(5):523–34. https://doi.org/10.1080/14740338.2017.1311321 PMID: 28333552

19. Neuhaus O, Kieseier BC, Hartung HP. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. Journal of the neurological sciences. 2007; 259(1–2):27–37. https://doi.org/10.1016/j.jns.2006.05.071 PMID: 17391705

20. Machado CJ. Impact of maternal age on birth outcomes: a population-based study of primiparous Brazilian women in the city of Sao Paulo. Journal ofbiosocial science. 2006; 38(4):523–35. https://doi.org/10.1017/S0021932005026660 PMID: 16762088

21. Yu SH, Mason J, Crum J, Cappa C, Hotchkiss DR. Differential effects of young maternal age on child growth. Global health action. 2016; 9:31171. https://doi.org/10.3402/gha.v9.31171 PMID: 27852422

22. Borja JB, Adair LS. Assessing the net effect of young maternal age on birthweight. American journal of human biology: the official journal of the Human Biology Council. 2003; 15(6):73–40.

23. Ergin I, Hassoy H, Tanik FA, Aslan G. Maternal age, education level and migration: socioeconomic determinants for smoking during pregnancy in a field study from Turkey. BMC public health. 2010; 10:325. https://doi.org/10.1186/1471-2458-10-325 PMID: 20534133

24. Thiel S, Langer-Gould A, Rockhoff M, Haghiakia A, Queisser-Wahrendorf A, Gold R, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis- A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Multiple sclerosis. 2016; 22(6):801–9. https://doi.org/10.1177/1352458516634872 PMID: 26920382

25. Juch H, Lupattelli A, Ystrom E, Verheyen S, Nordeng H. Medication adherence among pregnant women with hypothyroidism-missed opportunities to improve reproductive health? A cross-sectional, web-based study. Patient education and counseling. 2016; 99(10):1699–707. https://doi.org/10.1016/j.pec.2016.04.006 PMID: 27133920

26. Bailey H, Thorne C, Malyuta R, Townsend CL, Semenenko I, Cortina-Borja M, et al. Adherence to anti-retroviral therapy during pregnancy and the first year postpartum among HIV-positive women in Ukraine. BMC public health. 2014; 14:993. https://doi.org/10.1186/1471-2458-14-993 PMID: 25248469